EquitySectoral/ ThematicDirect · Growth
Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option
Nippon India · Scheme 118759
₹643.34▲ 0.28%NAV · 2026-09-18
Strong FundScore
AUM
₹9,279 cr
Expense ratio
0.99%
3Y CAGR
19.2%
Risk level
High
Min SIP
₹100
Benchmark
Nifty 500 TRI
Fund manager: Sailesh Raj BhanExit load: Exit load of 1% if redeemed within 1 month.
Strong · 72/100
A high-quality fund that scores well on the factors that matter.
🎯 For aggressive investors with a 7+ year horizon who can tolerate sharp ups and downs.
📈 Why it could do well
- ✓Compounding well recently — 19.2% CAGR over 3 years.
- ✓Very consistent — delivers dependably across market cycles, ideal for SIPs.
- ✓3Y CAGR: +19.2%
- ✓Positive 3Y windows: 98% of rolling 3Y windows positive
📉 What could drag it down
- •Sectoral/ Thematics are inherently higher-risk — best held 7+ years to ride out swings.
FundScore breakdown
72/100 · Strong
Returns
Strong
Consistency
Strong
Risk-adjusted
Decent
Downside protection
Excellent
Cost efficiency
Strong
Portfolio quality
Average
Each dial rates the fund 0–100 on one factor, computed from real NAV history. Fuller & greener = stronger.
SIP return calculator
Back-tested on this fund's actual historical NAVs. Past performance ≠ future returns.